title: The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.
abstract: OBJECTIVE
  To explore luteal phase hormone profiles in patients stimulated with recombinant FSH and GnRH antagonist for IVF under two different modes of luteal support: P and P with E(2).
  
  
  METHODS
  Prospective randomized study.
  
  
  METHODS
  Patients in an academic reproductive medicine unit.
  
  
  METHODS
  One hundred and three patients undergoing ovarian stimulation with a fixed dose of 200 IU recombinant FSH and GnRH antagonist.
  
  
  METHODS
  Patients were randomized to receive luteal phase supplementation, either P vaginally (n = 49) or P and 4 mg E(2) orally (n = 54).
  
  
  METHODS
  Hormonal assessment during the luteal phase on days 1, 4, 7, and 10 after the administration of hCG.
  
  
  RESULTS
  Hormone levels did not differ during the luteal phase between the two groups with the exception of E(2) concentration on day 10 after hCG, which was significantly higher in the E(2)-supplemented group compared with the P group (median 760 pg/mL, range 2,496 vs. median 589.50 pg/mL, range 2,098).
  
  
  CONCLUSIONS
  Addition of 4 mg E(2) for luteal support after stimulation with recombinant FSH and GnRH antagonist does not alter significantly the endocrine profile of the luteal phase until day 7 after hCG. At day 10 after hCG, the E(2) levels are significantly higher in the E(2)-supplemented group.
authors.affiliation: Centre for Reproductive Medicine, Dutch-Speaking Free University, Brussels, Belgium. hmousavi@az.vub.ac.be <hmousavi@az.vub.ac.be>
authors.forename: Human M
authors.initials: HM
authors.lastname: Fatemi
authors.forename: Michel
authors.initials: M
authors.lastname: Camus
authors.forename: Efstratios M
authors.initials: EM
authors.lastname: Kolibianakis
authors.forename: Herman
authors.initials: H
authors.lastname: Tournaye
authors.forename: Evangelos G
authors.initials: EG
authors.lastname: Papanikolaou
authors.forename: Patricio
authors.initials: P
authors.lastname: Donoso
authors.forename: Paul
authors.initials: P
authors.lastname: Devroey
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006801:Humans; D008183:Luteal Phase / Q000097:blood* / Q000187:drug effects; D011374:Progesterone / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000627:therapeutic use; D020554:Sperm Injections, Intracytoplasmic / Q000379:methods
chemical_list: D006063:Chorionic Gonadotropin; D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D005640:Follicle Stimulating Hormone; C061018:ganirelix